… In conclusion, the findings recommend dosing of piperacillin-tazobactam with the aim of
achieving a pharmacodynamic target %fT >MIC of at least 60% in these patients. …

… target attainments in ICU patients without renal dysfunction. Higher doses of piperacillin/tazobactam
would be needed to cover microorganisms with MIC > 8 mg/l. CrCL was the most …

… Similar conclusion was recently reported with meropenem and piperacillin-tazobactam, with
… Among the two reports of morbid obesity included in this review, both patients had altered …

… piperacillin/tazobactam and linezolid, with clinical resolution. … 1 mg/L, I suggest increasing
daptomycin dosage to 1500 mg … ceftobiprole dosage in morbidly obese critically ill patients. A …

… dosing strategy, ie, fixed dosing or mg/kg body weight. In individuals with obesity, it is
particularly important that dose … dosing strategy (fixed dosing or mg/kg dosing) to individuals with …

… obese patients receiving a β-lactam have worse clinical outcomes compared to nonobese
patients … This subsequently led to higher dosing recommendations based on patient weight …

… Conventional dosing of piperacillin-tazobactam is sub-optimal for patients in intensive care
… Administration and sampling methods for piperacillin-tazobactam in the studies included in …

… Weights influenced piperacillin/tazobactam, as the PTA decreased as the weight quartile …
dosing regimens for morbidly obese patients were 1 g every 8 h, 2 g every 8 h, 500 mg …

… Moreover, we investigated appropriate dosage regimens of piperacillin/tazobactam via
Monte Carlo simulations to predict the standard and aggressive PK/PD indices of 50%fT >MIC , …

… of the patients in our study had obesity and morbid obesity, and the most common disease
associated with SSTI was obesity. … In our study, piperacillin/tazobactam treatment with high anti…